News
We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are ...
3d
Zacks Investment Research on MSNEWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study DataShares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate ...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
1d
Zacks Investment Research on MSNBiotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & MoreIt was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...
Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 28.51%, which has investors questioning if this is right time to ...
Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX ...
Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its ...
As previously reported yesterday, Scotiabank downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a price target of ...
Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate, EDG-7500, in patients with obstructive or nonobstructive hypertrophic ...
Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate, EDG-7500, in patients with obstructive or nonobstructive hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results